This was evident in this study where the drug obviously exhibited a higher ameliorative effect in BPH markers (PSA levels, prostate weight, relative prostate weight and prostate protein content) compared to AFAL, though the differences were not statistically significant. This evidence concerns the gene KLK3 and benign prostatic hyperplasia.